


A Fucoidan- based Neutraceutical

Algae power to prevent
Alzheimer and other
neurodegenerative diseases




Demand



- Someone in the world develops dementia every 3 seconds
- Today 1.9 million people affected by dementia in Germany, **60 million people worldwide**, reaching **139 million in 2050**
- Costs by dementia will then reach **US\$ 2.8 trillion**

WHO 2021



Neuroprotection by fucoïdan

Transfer of knowledge about neuroprotecting activities of fucoïdan:

- Strong overexpression (human cell lines) of a specific protein, that play a significant role in the **degradation of β -amyloïds**

(BMBF-funded project „AAC – Algae Against Cancer“)



Development Challenges

- 1 Design, optimisation, upscaling of **algae-processing** steps
- 2 Preparation of clinical studies - **preclinical tests**
- 3 Requirements of application for a new **health claim**
- 4 Product and marketing **specifications** and sustainability check



Risks

- 1 High costs** for studies and health claim application
- 2 Uneconomical upscaling** of laboratory extraction methods



Chances

- 1 Helping to fight some the **most serious** chronic diseases
- 2 Reaching a **huge market**

2028: Launch of “my Brain Shield“

Supporting degradation of β -Amyloid-Plaque

Thank you

